1.55
2.52%
-0.04
시간 외 거래:
1.62
0.07
+4.52%
전일 마감가:
$1.59
열려 있는:
$1.57
하루 거래량:
78,828
Relative Volume:
0.19
시가총액:
$9.45M
수익:
$743.00K
순이익/손실:
$-7.63M
주가수익비율:
-0.5167
EPS:
-3
순현금흐름:
-
1주 성능:
-1.90%
1개월 성능:
+9.15%
6개월 성능:
-57.42%
1년 성능:
-22.50%
캔 파이트 바이오파마 Stock (CANF) Company Profile
명칭
Can-Fite Biopharma Ltd ADR
전화
972 3 924 1114
주소
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
CANF을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
1.55 | 9.45M | 743.00K | -7.63M | 0 | -3.00 |
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
캔 파이트 바이오파마 Stock (CANF) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2017-08-11 | 개시 | Maxim Group | Buy |
2016-10-19 | 재개 | ROTH Capital | Buy |
2016-08-29 | 재개 | Rodman & Renshaw | Buy |
2015-11-30 | 재확인 | H.C. Wainwright | Buy |
2015-03-31 | 재확인 | H.C. Wainwright | Buy |
2015-03-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2014-12-29 | 재확인 | ROTH Capital | Buy |
2014-11-18 | 개시 | H.C. Wainwright | Buy |
모두보기
캔 파이트 바이오파마 주식(CANF)의 최신 뉴스
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions - Business Wire
Cronos Group Inc (NASDAQ: CRON) Could Slash -12.75% Soon - Stocks Register
Commercial Metals Co (NYSE: CMC) Could Slash -1.03% Soon - Stocks Register
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com India
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewswire Inc.
Can-Fite secures Australian patent for obesity treatment - Investing.com
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of WeRide Inc. - Business Wire
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India
Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is CANF’s price-to-sales ratio telling us about the company’s value? - US Post News
Taking on analysts’ expectations and winning: Can-Fite Biopharma Ltd ADR (CANF) - SETE News
Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex
CANF (Can-Fite Biopharma Ltd ADR) has impressive results - US Post News
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com
Can-Fite BioPharma shares upgraded by EF Hutton to Buy on pipeline drugs - Investing.com
Canine arthritis treatment shows promise in clinical study - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Can-Fite Announces ADS Ratio Change - Business Wire
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates - Nasdaq
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC
캔 파이트 바이오파마 (CANF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):